Despite this caveat, hematopoietic stem/progenitor cell (HSPC) antigens with increased expression on AML blasts, such as CD33, CD123, and CLL1 (CLEC12A), have emerged as potential targets. Here, CD33 is linked to acute myeloid leukemia.